{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T15:30:30Z","timestamp":1762443030966,"version":"build-2065373602"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017638","name":"Ministry of Health of the Russian Federation","doi-asserted-by":"publisher","award":["AAAA-\u041119-219091390048-6","AAAA-A18-118100890050-5"],"award-info":[{"award-number":["AAAA-\u041119-219091390048-6","AAAA-A18-118100890050-5"]}],"id":[{"id":"10.13039\/501100017638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11095-025-03919-y","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:41:58Z","timestamp":1759336918000},"page":"1701-1715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single- and Multiple-dose Pharmacokinetics, Excretion, Metabolism, and Safety of the Antivirulence Agent Fluorothiazinone in Healthy Adults"],"prefix":"10.1007","volume":"42","author":[{"given":"Mark V.","family":"Savitskii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-8913","authenticated-orcid":false,"given":"Natalia E.","family":"Moskaleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana A.","family":"Appolonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Brito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia E.","family":"Bondareva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadezhda L.","family":"Lubenec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna B.","family":"Sheremet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria K.","family":"Ordzhonikidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nailya A.","family":"Zigangirova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey K.","family":"Zyryanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim V.","family":"Tarasov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander L.","family":"Gintsburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"3919_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/fmb-2019-0294","volume":"15","author":"S Buroni","year":"2020","unstructured":"Buroni S, Chiarelli LR. Antivirulence compounds: a future direction to overcome antibiotic resistance? Future Microbiol. 2020;15:299\u2013301.","journal-title":"Future Microbiol"},{"key":"3919_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrd3013","volume":"9","author":"DA Rasko","year":"2010","unstructured":"Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov. 2010;9:117\u201328.","journal-title":"Nat Rev Drug Discov"},{"key":"3919_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","volume":"387","author":"AH Holmes","year":"2016","unstructured":"Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet. 2016;387:176\u201387.","journal-title":"The Lancet"},{"key":"3919_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41429-020-0344-z","volume":"74","author":"H Ogawara","year":"2021","unstructured":"Ogawara H. Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs. J Antibiot (Tokyo). 2021;74:24\u201341.","journal-title":"J Antibiot (Tokyo)"},{"key":"3919_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/484853","volume":"2015","author":"EA Koroleva","year":"2015","unstructured":"Koroleva EA, Kobets NV, Zayakin ES, Luyksaar SI, Shabalina LA, Zigangirova NA. Small Molecule Inhibitor of Type Three Secretion Suppresses Acute and Chronic Chlamydia trachomatis Infection in a Novel Urogenital Chlamydia Model. BioMed Res Int. 2015;2015:1\u20137.","journal-title":"BioMed Res Int"},{"key":"3919_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/ja.2015.131","volume":"69","author":"LN Nesterenko","year":"2016","unstructured":"Nesterenko LN, Zigangirova NA, Zayakin ES, Luyksaar SI, Kobets NV, Balunets DV, et al. A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones suppresses Salmonella infection in vivo. J Antibiot (Tokyo). 2016;69:422\u20137.","journal-title":"J Antibiot (Tokyo)"},{"key":"3919_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41429-020-00396-w","volume":"74","author":"NA Zigangirova","year":"2021","unstructured":"Zigangirova NA, Nesterenko LN, Sheremet AB, Soloveva AV, Luyksaar SI, Zayakin ES, et al. Fluorothiazinon, a small-molecular inhibitor of T3SS, suppresses salmonella oral infection in mice. J Antibiot (Tokyo). 2021;74:244\u201354.","journal-title":"J Antibiot (Tokyo)"},{"key":"3919_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5810767","volume":"2018","author":"AB Sheremet","year":"2018","unstructured":"Sheremet AB, Zigangirova NA, Zayakin ES, Luyksaar SI, Kapotina LN, Nesterenko LN, et al. Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas aeruginosa Infection in Mice. BioMed Res Int. 2018;2018:1\u201313.","journal-title":"BioMed Res Int"},{"key":"3919_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41429-023-00621-2","volume":"76","author":"SV Tsarenko","year":"2023","unstructured":"Tsarenko SV, Zigangirova NA, Soloveva AV, Bondareva NE, Koroleva EA, Sheremet AB, et al. A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia. J Antibiot (Tokyo). 2023;76:397\u2013405.","journal-title":"J Antibiot (Tokyo)"},{"key":"3919_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41429-022-00504-y","volume":"75","author":"NE Bondareva","year":"2022","unstructured":"Bondareva NE, Soloveva AV, Sheremet AB, Koroleva EA, Kapotina LN, Morgunova EY, et al. Preventative treatment with Fluorothiazinon suppressed Acinetobacter baumannii-associated septicemia in mice. J Antibiot (Tokyo). 2022;75:155\u201363.","journal-title":"J Antibiot (Tokyo)"},{"key":"3919_CR11","unstructured":"Koroleva EA, Soloveva AV, Morgunova EY, Kapotina LN, Luyksaar SI, Luyksaar SV, et al. Fluorothiazinon inhibits the virulence factors of uropathogenic Escherichia coli involved in the development of urinary tract infection. J Antibiot (Tokyo). 2023; Available from: https:\/\/www.nature.com\/articles\/s41429-023-00602-5. Accessed 30 Mar 2023"},{"key":"3919_CR12","first-page":"476","volume":"13","author":"NA Zigangirova","year":"2024","unstructured":"Zigangirova NA, Lubenec NL, Beloborodov VB, Sheremet AB, Nelyubina SA, Bondareva NE, et al. A New, \u201cNon-Traditional\u201d Antibacterial Drug Fluorothiazinone-Clinical Research in Patients with Complicated Urinary Tract Infections. Antibiot Basel Switz. 2024;13:476.","journal-title":"Antibiot Basel Switz"},{"key":"3919_CR13","doi-asserted-by":"publisher","first-page":"115739","DOI":"10.1016\/j.jpba.2023.115739","volume":"236","author":"MV Savitskii","year":"2023","unstructured":"Savitskii MV, Moskaleva NE, Brito A, Zigangirova NA, Soloveva AV, Sheremet AB, et al. Pharmacokinetics, quorum-sensing signal molecules and tryptophan-related metabolomics of the novel anti-virulence drug Fluorothiazinon in a Pseudomonas aeruginosa-induced pneumonia murine model. J Pharm Biomed Anal. 2023;236:115739.","journal-title":"J Pharm Biomed Anal"},{"key":"3919_CR14","unstructured":"Savitskii MV, Moskaleva NE, Brito A, Markin PA, Zigangirova NA, Soloveva AV, et al. Pharmacokinetics, tissue distribution, bioavailability and excretion of the anti-virulence drug Fluorothiazinon in rats and rabbits. J Antibiot (Tokyo) [Internet]. 2024; Available from: https:\/\/www.nature.com\/articles\/s41429-024-00719-1. Accessed 18 Mar 2024."},{"key":"3919_CR15","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/cpt.2073","volume":"109","author":"JC Walton","year":"2021","unstructured":"Walton JC, Walker WH, Bumgarner JR, Mel\u00e9ndez-Fern\u00e1ndez OH, Liu JA, Hughes HL, et al. Circadian Variation in Efficacy of Medications. Clin Pharmacol Ther. 2021;109:1457\u201388.","journal-title":"Clin Pharmacol Ther"},{"key":"3919_CR16","doi-asserted-by":"publisher","first-page":"114045","DOI":"10.1016\/j.bcp.2020.114045","volume":"178","author":"D Dong","year":"2020","unstructured":"Dong D, Yang D, Lin L, Wang S, Wu B. Circadian rhythm in pharmacokinetics and its relevance to chronotherapy. Biochem Pharmacol. 2020;178:114045.","journal-title":"Biochem Pharmacol"},{"key":"3919_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1517\/17425255.4.2.175","volume":"4","author":"M Baraldo","year":"2008","unstructured":"Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol. 2008;4:175\u201392.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3919_CR18","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s11094-024-03083-4","volume":"57","author":"SN Baskhanova","year":"2024","unstructured":"Baskhanova SN, Savitskii MV, Moskaleva NE, Samoylov VM, Lubenec NL, Luyksaar SI, et al. Development and Validation of a Quantitative Determination Method for Fluorothiazinone in Human Blood Plasma. Pharm Chem J. 2024;57:1815\u201321.","journal-title":"Pharm Chem J"},{"key":"3919_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jpba.2017.02.006","volume":"138","author":"NE Moskaleva","year":"2017","unstructured":"Moskaleva NE, Baranov PA, Mesonzhnik NV, Appolonova SA. HPLC\u2013MS\/MS method for the simultaneous quantification of desmethylmebeverine acid, mebeverine acid and mebeverine alcohol in human plasma along with its application to a pharmacokinetics study. J Pharm Biomed Anal. 2017;138:118\u201325.","journal-title":"J Pharm Biomed Anal"},{"key":"3919_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11419-017-0364-y","volume":"35","author":"S Savchuk","year":"2017","unstructured":"Savchuk S, Appolonova S, Pechnikov A, Rizvanova L, Shestakova K, Tagliaro F. In vivo metabolism of the new synthetic cannabinoid APINAC in rats by GC\u2013MS and LC\u2013QTOF-MS. Forensic Toxicol. 2017;35:359\u201368.","journal-title":"Forensic Toxicol"},{"key":"3919_CR21","first-page":"95","volume":"54","author":"R Dedrick","year":"1970","unstructured":"Dedrick R, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep. 1970;54:95\u2013101.","journal-title":"Cancer Chemother Rep"},{"key":"3919_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/BF01059667","volume":"1","author":"RL Dedrick","year":"1973","unstructured":"Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm. 1973;1:435\u201361.","journal-title":"J Pharmacokinet Biopharm"},{"key":"3919_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF01062336","volume":"10","author":"H Boxenbaum","year":"1982","unstructured":"Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm. 1982;10:201\u201327.","journal-title":"J Pharmacokinet Biopharm"},{"key":"3919_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.18683\/germs.2022.1328","volume":"12","author":"R Dehbanipour","year":"2022","unstructured":"Dehbanipour R, Ghalavand Z. Anti-virulence therapeutic strategies against bacterial infections: recent advances. Germs. 2022;12:262\u201375.","journal-title":"Germs"},{"key":"3919_CR25","doi-asserted-by":"crossref","unstructured":"Ghazaei C. Anti-virulence Therapy Against Bacterial Infections: Mechanisms of Action and Challenges. J Kermanshah Univ Med Sci [Internet]. 2021;25. Available from: https:\/\/brieflands.com\/articles\/jkums-111808.html. Accessed 12 Jan 2024.","DOI":"10.5812\/jkums.111808"},{"key":"3919_CR26","doi-asserted-by":"publisher","first-page":"104429","DOI":"10.1016\/j.ebiom.2022.104429","volume":"88","author":"WYV Lau","year":"2023","unstructured":"Lau WYV, Taylor PK, Brinkman FSL, Lee AHY. Pathogen-associated gene discovery workflows for novel antivirulence therapeutic development. eBioMedicine. 2023;88:104429.","journal-title":"eBioMedicine"},{"key":"3919_CR27","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1038\/s41564-024-01856-x","volume":"9","author":"N Proch\u00e1zkov\u00e1","year":"2024","unstructured":"Proch\u00e1zkov\u00e1 N, Laursen MF, La Barbera G, Tsekitsidi E, J\u00f8rgensen MS, Rasmussen MA, et al. Gut physiology and environment explain variations in human gut microbiome composition and metabolism. Nat Microbiol. 2024;9:3210\u201325.","journal-title":"Nat Microbiol"},{"key":"3919_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.33647\/2074-5982-19-1-73-84","volume":"19","author":"MV Savitskii","year":"2023","unstructured":"Savitskii MV, Moskaleva NE, Zigangirova NA, Soloveva AV, Sheremet AB, Bondareva NE, et al. Experimental Pharmacokinetics, Metabolism and Tissue Distribution Studies Fluorothiazinon, a of Novel Antivirulence Drug. J Biomed. 2023;19:73\u201384.","journal-title":"J Biomed"},{"issue":"7","key":"3919_CR29","first-page":"57","volume":"25","author":"VM Samojlov","year":"2023","unstructured":"Samojlov VM, Savitskii MV, Baskhanova SN, Romashkina AG, Appolonova SA. Pharmacokinetics of solid dispersion and crystalline forms of the anti-virulence drug fluorothiazinon in rats. Med Pharm J Pulse. 2023;25(7):57\u201362.","journal-title":"Med Pharm J Pulse."},{"key":"3919_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199120060-00001","volume":"20","author":"TM Ludden","year":"1991","unstructured":"Ludden TM. Nonlinear Pharmacokinetics: Clinical Implications. Clin Pharmacokinet. 1991;20:429\u201346.","journal-title":"Clin Pharmacokinet"},{"key":"3919_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/03602532.2017.1293682","volume":"49","author":"G Yang","year":"2017","unstructured":"Yang G, Ge S, Singh R, Basu S, Shatzer K, Zen M, et al. Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metab Rev. 2017;49:105\u201338.","journal-title":"Drug Metab Rev"},{"key":"3919_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-024-01444-6","volume":"64","author":"DW Van Valkengoed","year":"2025","unstructured":"Van Valkengoed DW, Krekels EHJ, Knibbe CAJ. All You Need to Know About Allometric Scaling: An Integrative Review on the Theoretical Basis, Empirical Evidence, and Application in Human Pharmacology. Clin Pharmacokinet. 2025;64:173\u201392.","journal-title":"Clin Pharmacokinet"},{"key":"3919_CR33","doi-asserted-by":"publisher","first-page":"1563450","DOI":"10.3389\/fimmu.2025.1563450","volume":"16","author":"W Ding","year":"2025","unstructured":"Ding W, Cheng Y, Liu X, Zhu Z, Wu L, Gao J, et al. Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria. Front Immunol. 2025;16:1563450.","journal-title":"Front Immunol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03919-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03919-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03919-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T15:28:23Z","timestamp":1762442903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03919-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3919"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03919-y","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}